PI3K — phosphatidylinositol 3-kinase — is the lipid kinase that phosphorylates membrane phosphatidylinositol-4,5-bisphosphate to generate PIP3, the membrane signal that recruits Akt to the plasma membrane and triggers the activation cascade downstream of receptor engagement.
Definition
Phosphatidylinositol 3-kinase is a family of lipid kinases that catalyse phosphorylation of the 3-hydroxyl on the inositol ring of membrane phosphoinositides. The class IA enzymes — the family most directly relevant to growth-factor signalling and the peptide-research literature — are heterodimers of a catalytic subunit (p110α, p110β, or p110δ) and a regulatory subunit (p85α and related variants). The regulatory subunit carries SH2 domains that dock onto phosphotyrosine residues on activated receptor tyrosine kinases, recruiting the catalytic subunit to the membrane and switching it into its active conformation.
Once active, PI3K phosphorylates membrane PIP2 to generate PIP3. PIP3 is a transient membrane lipid that serves as a docking platform for any protein carrying a pleckstrin-homology (PH) domain — including Akt and its upstream activating kinase PDK1. PIP3 generation is the critical membrane signal that converts receptor engagement into intracellular kinase-cascade activation, and PIP3 levels are tightly opposed by the PTEN phosphatase which removes the 3-phosphate.
How PI3K is studied in peptide research
PI3K involvement in a peptide’s signalling response is established by pharmacological inhibition with LY294002 or wortmannin, with the inhibitor’s blockade of Akt phosphorylation and downstream functional outcomes implicating the PI3K-Akt axis as causal. Direct measurement of PI3K activity uses lipid-kinase assays on immunoprecipitated enzyme. Genetic loss-of-function in p110 catalytic subunits or knockdown of regulatory-subunit isoforms provides independent confirmation in cell and animal models.
For BPC-157, the VEGFR2 → PI3K → Akt → eNOS cascade is the most-cited mechanistic chain, with VEGFR2 engagement on vascular endothelial cells coupling through PI3K-mediated PIP3 generation to Akt phosphorylation and downstream nitric oxide release (PMID 27847966). The synthesis in the broader BPC-157 NO-system literature (PMID 23755725) and in the major-vessel-occlusion / collateral-circulation work (PMID 35125818) extend the framing across ischemic-stress models. The 2024 comprehensive review integrates PI3K-Akt-axis findings into a unified cytoprotection map (PMID 38980576).
Related terms
- Akt signalling
- VEGFR2
- Tyrosine kinase receptor
- mTOR / mechanistic target of rapamycin
- PIP3 / phosphatidylinositol (3,4,5)-trisphosphate
- PTEN phosphatase
- PDK1
Compounds where PI3K appears in the mechanism literature
- BPC-157 — PI3K is the upstream lipid-kinase step in the VEGFR2-Akt-eNOS cascade
- TB-500 — PI3K-Akt signalling overlaps with the integrin-linked kinase axis in endothelial-cell migration and survival outcomes
- GHK-Cu — copper-dependent signalling intersects with PI3K-Akt in fibroblast and keratinocyte models
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
- Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World J Gastroenterol 2022;28(1):1-22. [PMID 35125818]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Glossary entries describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.